Opinion on Therapy Area in United Kingdom

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
ResearchWire
ResearchWire

Asthma: UK top for diagnosis, US bottom

Published By Datamonitor
04 Feb 2002
ResearchWire
ResearchWire

Asthma: US prevalence increasing by 2.1% a year

Published By Datamonitor
12 Jun 2002
Expert View
Expert View

AstraZeneca on the acquisition trail

UK drug manufacturer AstraZeneca ended 2005 on a high note, making four significant acquisitions in December. This spending spree comprised the acquisition of product rights for one phase III drug and two phase II products, alongside the purchase of UK-based biotech firm KuDOS Pharmaceuticals. With these purchases, AstraZeneca aims to bolster its pipeline in both the short and long term.

Published By Datamonitor
04 Jan 2006
CommentWire
CommentWire

AstraZeneca/Targacept: another nail in the coffin for TC-5214

New top-line data show that the innovative nicotinic receptor antagonist TC-5214 has once again failed to demonstrate efficacy as an add-on to antidepressants in patients with major depressive disorder. Approval now seems highly unlikely, leaving Targacept without a lead candidate and AstraZeneca with a hefty loss.

Published By Datamonitor
20 Dec 2011
CommentWire
CommentWire

AstraZeneca: Arimidex is the new gold standard

The cancer drug showed outstanding results compared to the current gold standard, tamoxifen. Indeed, Arimidex could be the ideal aromatase inhibitor - and judging by these results, AstraZeneca's marketing power will ensure that the drug becomes a major cancer product.

Published By Datamonitor
19 Feb 2002
CommentWire
CommentWire

AstraZeneca: blockbuster status remains distant for Iressa

AstraZeneca's [AZN.L] Iressa was billed as one of a new class of anti-tumor agents that would revolutionize the treatment of lung cancer. However, to date the drug has been disappointing and approvals continue to be for third-line treatment. If Iressa is to reach blockbuster status, it must reach patients as a first line therapy.

Published By Datamonitor
05 Jan 2004
CommentWire
CommentWire

AstraZeneca: cancer drug to find lost revenues

The approval of Iressa in the US, just days after the approval in Australia, may help AstraZeneca to recover from a drop in sales of Prilosec following the launch of a generic competitor. However, there remains controversy surrounding Iressa's side effects.

Published By Datamonitor
08 May 2003
CommentWire
CommentWire

AstraZeneca: compliance complacency over Seroquel

Extrapyramidal symptoms are among antipsychotics' worst side effects; compliance is a huge barrier in treating schizophrenia patients; and Seroquel causes lower levels of EPS than its rivals. So it's unsurprising that AstraZeneca is trying to cash in. However, the company needs to develop an intramuscular formulation to keep up with rival drugs.

Published By Datamonitor
30 May 2002
CommentWire
CommentWire

AstraZeneca: dropping another drug

AstraZeneca has dropped its stroke treatment NXY-059 after the drug failed to show statistically significant reduction in stroke-related disability in a recent study. The news is yet another high-profile setback for the pharmaceutical company which has seen several drug failures recently and, with other pipeline projects looking risky, there may be more to come.

Published By Datamonitor
27 Oct 2006
CommentWire
CommentWire

AstraZeneca: Exanta results biased by design

Although a new trial has found AstraZeneca's Exanta more effective than Aventis' Lovenox at cutting venous thromboembolism incidence, the trial's design does not inspire confidence in the results - or in Exanta as a VTE drug. AstraZeneca's anticoagulant has far greater potential as a replacement for warfarin for stroke prevention in atrial fibrillation patients.<BR />

Published By Datamonitor
30 Oct 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.